Bioventus, Inc. (BVS)
|Net Income (ttm)||19.27M|
|Trading Day||March 5|
|Day's Range||10.74 - 11.93|
|52-Week Range||10.74 - 19.51|
DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that fourth qua...
Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering...
DURHAM, N.C.--Bioventus Inc. ("Bioventus" or the “Company”), today announced that it has commenced the initial public offering of its Class A common stock. Bioventus is offering 7,350,000 shar...
RESEARCH TRIANGLE PARK - Biotech companies continue to jump in line to join the public markets. Bioventus, a medical device maker whose portfolio includes...
This is the second time North Carolina medical device maker applied to go public via an initial public offering. In 2016, the company rescinded its application citing market conditions.
Bioventus, which offers orthobiologics products for musculoskeletal conditions, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company had previ...
Bioventus, Inc. has filed to go public with an IPO on the NASDAQ.
Bioventus focuses on operating as a holding company for Bioventus LLC that operates as a medical device company. It develops and commercializes clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived... [Read more...]
|IPO Date |
Feb 11, 2021
Kenneth M. Reali
|Stock Exchange |
|Ticker Symbol |